PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
19189661-12	2008	RESULTS: In vitro: Proliferation of Hep 3B, PLC/PRF/5 and SKHEP-1 HCC cells was significantly inhibited at all EB1089 concentrations tested, while HTC cells only responded to 1000 nM concentration of EB1089.	seocalcitol	111-117	heparan sulfate proteoglycan 2	Homo sapiens	44-47
19160095-0	2009	EB1089 induces Skp2-dependent p27 accumulation, leading to cell growth inhibition and cell cycle G1 phase arrest in human hepatoma cells.	seocalcitol	0-6	S-phase kinase associated protein 2	Homo sapiens	15-19
19160095-0	2009	EB1089 induces Skp2-dependent p27 accumulation, leading to cell growth inhibition and cell cycle G1 phase arrest in human hepatoma cells.	seocalcitol	0-6	zinc ribbon domain containing 2	Homo sapiens	30-33
19160095-6	2009	Taken together, our data indicate that EB1089 inhibitory activity is associated with alteration of cell cycle checkpoints through Skp2-dependent p27 induction in Hep-G2 cells.	seocalcitol	39-45	S-phase kinase associated protein 2	Homo sapiens	130-134
19160095-6	2009	Taken together, our data indicate that EB1089 inhibitory activity is associated with alteration of cell cycle checkpoints through Skp2-dependent p27 induction in Hep-G2 cells.	seocalcitol	39-45	zinc ribbon domain containing 2	Homo sapiens	145-148
15569516-4	2004	RESULTS: EB1089 could inhibit the proliferation of hepatocellular cell line Hep-G(2) that expressed prominent vitamin D receptor mRNA, the inhibitory rate is 17.5% approximately 72.1%.	seocalcitol	9-15	vitamin D receptor	Homo sapiens	110-128
18483314-0	2008	Vitamin D3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57.	seocalcitol	20-26	cyclin dependent kinase inhibitor 1C	Homo sapiens	102-105
15905882-0	2005	Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death.	seocalcitol	17-23	beclin 1	Homo sapiens	64-72
17286279-2	2007	In VDR-expressing WT145 cells, 1,25D and its synthetic analog EB1089 induce growth arrest and transcriptionally upregulate the well-characterized VDR target gene CYP24.	seocalcitol	62-68	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	3-6
17286279-2	2007	In VDR-expressing WT145 cells, 1,25D and its synthetic analog EB1089 induce growth arrest and transcriptionally upregulate the well-characterized VDR target gene CYP24.	seocalcitol	62-68	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	146-149
17286279-2	2007	In VDR-expressing WT145 cells, 1,25D and its synthetic analog EB1089 induce growth arrest and transcriptionally upregulate the well-characterized VDR target gene CYP24.	seocalcitol	62-68	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	162-167
16800739-9	2006	In some breast cancer cell lines, KLK6 expression could be restored by the vitamin D3 analog EB1089.	seocalcitol	93-99	kallikrein related peptidase 6	Homo sapiens	34-38
16115727-0	2005	EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer.	seocalcitol	0-6	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	10-28
15270590-7	2004	The association of antioxidants (N-acetyl cysteine, superoxide dismutase, catalase) with VD(3) or EB1089 induce a more limited autofluorescence decrease and a weaker ROS generation, as compared with VD(3) and EB1089 treated cells.	seocalcitol	98-104	catalase	Homo sapiens	74-82
12446453-0	2003	The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro.	seocalcitol	22-28	tumor protein p53	Homo sapiens	53-56
15055995-0	2004	Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance.	seocalcitol	119-130	vitamin D receptor	Homo sapiens	26-52
15055995-4	2004	Here, we report the crystal structures of VDR ligand binding domain bound to two vitamin D agonists of therapeutical interest, calcipotriol and seocalcitol, which are characterized by their side chain modifications.	seocalcitol	144-155	vitamin D receptor	Homo sapiens	42-45
15055995-7	2004	The VDR-seocalcitol structure, in comparison with the structure of VDR-KH1060, a superagonist ligand closely related to seocalcitol, shows adaptation of the D ring and position of C-21 in order to adapt its more rigid side chain.	seocalcitol	8-19	vitamin D receptor	Homo sapiens	4-7
15055995-7	2004	The VDR-seocalcitol structure, in comparison with the structure of VDR-KH1060, a superagonist ligand closely related to seocalcitol, shows adaptation of the D ring and position of C-21 in order to adapt its more rigid side chain.	seocalcitol	8-19	vitamin D receptor	Homo sapiens	67-70
15055995-7	2004	The VDR-seocalcitol structure, in comparison with the structure of VDR-KH1060, a superagonist ligand closely related to seocalcitol, shows adaptation of the D ring and position of C-21 in order to adapt its more rigid side chain.	seocalcitol	120-131	vitamin D receptor	Homo sapiens	4-7
15055995-7	2004	The VDR-seocalcitol structure, in comparison with the structure of VDR-KH1060, a superagonist ligand closely related to seocalcitol, shows adaptation of the D ring and position of C-21 in order to adapt its more rigid side chain.	seocalcitol	120-131	vitamin D receptor	Homo sapiens	67-70
12446453-0	2003	The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro.	seocalcitol	22-28	mitogen-activated protein kinase 14	Homo sapiens	89-92
12446453-0	2003	The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro.	seocalcitol	22-28	mitogen-activated protein kinase 1	Homo sapiens	134-137
12446453-7	2003	EB1089-induced apoptosis was preceded by activation of p38 mitogen-activated protein (MAP) kinase and suppression of extracellular signal-regulated kinase (ERK) activity, and this was associated with downstream activation of caspase-3.	seocalcitol	0-6	mitogen-activated protein kinase 14	Homo sapiens	55-58
12446453-7	2003	EB1089-induced apoptosis was preceded by activation of p38 mitogen-activated protein (MAP) kinase and suppression of extracellular signal-regulated kinase (ERK) activity, and this was associated with downstream activation of caspase-3.	seocalcitol	0-6	mitogen-activated protein kinase 1	Homo sapiens	117-154
12446453-7	2003	EB1089-induced apoptosis was preceded by activation of p38 mitogen-activated protein (MAP) kinase and suppression of extracellular signal-regulated kinase (ERK) activity, and this was associated with downstream activation of caspase-3.	seocalcitol	0-6	mitogen-activated protein kinase 1	Homo sapiens	156-159
12446453-7	2003	EB1089-induced apoptosis was preceded by activation of p38 mitogen-activated protein (MAP) kinase and suppression of extracellular signal-regulated kinase (ERK) activity, and this was associated with downstream activation of caspase-3.	seocalcitol	0-6	caspase 3	Homo sapiens	225-234
12446453-8	2003	The pancaspase inhibitor (Z-VAD-FMK) and the caspase-9 inhibitor (Z-LEHD-FMK) were able to partially abrogate the apoptotic effects of EB1089 but did not affect the phosphorylation of p38 MAP kinase or the suppression of ERK.	seocalcitol	135-141	caspase 9	Homo sapiens	45-54
12778867-4	2003	In this study we have analysed if calcitriol, Paricalcitol (19-nor-1,25-dihydroxy-vitamin D2) and EB1089 (experimental analog used as anticancerous) modify proliferation and the expression of vitamin D receptor (VDR) gene that is regulated at the transcriptional level by itself in the VSMCs.	seocalcitol	98-104	vitamin D receptor	Homo sapiens	192-210
12644300-12	2003	This data conclusively demonstrate that the induction of cell cycle arrest and apoptosis in breast cancer cells by 1,25D(3), EB1089 and CB1093 is dependent on the nuclear VDR.	seocalcitol	125-131	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	171-174
12778867-4	2003	In this study we have analysed if calcitriol, Paricalcitol (19-nor-1,25-dihydroxy-vitamin D2) and EB1089 (experimental analog used as anticancerous) modify proliferation and the expression of vitamin D receptor (VDR) gene that is regulated at the transcriptional level by itself in the VSMCs.	seocalcitol	98-104	vitamin D receptor	Homo sapiens	212-215
11836565-4	2002	TGF-beta1 intensified the decreased expression of CDK2, CDK4, CDK6 and cyclin D1 in EB1089-treated NCI-H929 cells.	seocalcitol	84-90	transforming growth factor beta 1	Homo sapiens	0-9
12408227-0	2002	Vitamin D and its analog EB1089 induce p27 accumulation and diminish association of p27 with Skp2 independent of PTEN in pituitary corticotroph cells.	seocalcitol	25-31	zinc ribbon domain containing 2	Homo sapiens	39-42
12408227-0	2002	Vitamin D and its analog EB1089 induce p27 accumulation and diminish association of p27 with Skp2 independent of PTEN in pituitary corticotroph cells.	seocalcitol	25-31	zinc ribbon domain containing 2	Homo sapiens	84-87
12408227-0	2002	Vitamin D and its analog EB1089 induce p27 accumulation and diminish association of p27 with Skp2 independent of PTEN in pituitary corticotroph cells.	seocalcitol	25-31	S-phase kinase associated protein 2	Homo sapiens	93-97
12408227-0	2002	Vitamin D and its analog EB1089 induce p27 accumulation and diminish association of p27 with Skp2 independent of PTEN in pituitary corticotroph cells.	seocalcitol	25-31	phosphatase and tensin homolog	Homo sapiens	113-117
11836565-4	2002	TGF-beta1 intensified the decreased expression of CDK2, CDK4, CDK6 and cyclin D1 in EB1089-treated NCI-H929 cells.	seocalcitol	84-90	cyclin dependent kinase 2	Homo sapiens	50-54
11836565-4	2002	TGF-beta1 intensified the decreased expression of CDK2, CDK4, CDK6 and cyclin D1 in EB1089-treated NCI-H929 cells.	seocalcitol	84-90	cyclin dependent kinase 4	Homo sapiens	56-60
11836565-4	2002	TGF-beta1 intensified the decreased expression of CDK2, CDK4, CDK6 and cyclin D1 in EB1089-treated NCI-H929 cells.	seocalcitol	84-90	cyclin dependent kinase 6	Homo sapiens	62-66
11836565-4	2002	TGF-beta1 intensified the decreased expression of CDK2, CDK4, CDK6 and cyclin D1 in EB1089-treated NCI-H929 cells.	seocalcitol	84-90	cyclin D1	Homo sapiens	71-80
11836565-7	2002	EB1089 caused the induction of SMAD4, a mediator of TGF-beta1 signaling.	seocalcitol	0-6	SMAD family member 4	Homo sapiens	31-36
11836565-7	2002	EB1089 caused the induction of SMAD4, a mediator of TGF-beta1 signaling.	seocalcitol	0-6	transforming growth factor beta 1	Homo sapiens	52-61
11839571-5	2002	VD and EB1089 induced increased nuclear protein expression of the cyclin-dependent kinase inhibitor, p27(kip1) (p27).	seocalcitol	7-13	cyclin dependent kinase inhibitor 1B	Homo sapiens	101-110
11839571-5	2002	VD and EB1089 induced increased nuclear protein expression of the cyclin-dependent kinase inhibitor, p27(kip1) (p27).	seocalcitol	7-13	interferon alpha inducible protein 27	Homo sapiens	101-104
11473365-10	2001	Therefore, EB1089 induces autocrine TGFbeta activity through increasing expression of TGFbeta isoforms and/or TGFbeta receptors.	seocalcitol	11-17	transforming growth factor beta 1	Homo sapiens	36-43
11473365-10	2001	Therefore, EB1089 induces autocrine TGFbeta activity through increasing expression of TGFbeta isoforms and/or TGFbeta receptors.	seocalcitol	11-17	transforming growth factor beta 1	Homo sapiens	86-93
11473365-10	2001	Therefore, EB1089 induces autocrine TGFbeta activity through increasing expression of TGFbeta isoforms and/or TGFbeta receptors.	seocalcitol	11-17	transforming growth factor beta 1	Homo sapiens	86-93
11473365-16	2001	We found that the PI 3-kinase pathway inhibitor LY29004 inhibited the synergy of TGFbeta and EB1089 on VDR-dependent transactivation activity.	seocalcitol	93-99	vitamin D receptor	Homo sapiens	103-106
10786699-6	2000	1alpha,25-Dihydroxyvitamin D3 and EB1089 induced p53-independent apoptosis in adenoma and carcinoma cell lines in a dose-dependent manner between 10(-10) and 10(-6) M. EB1089, as well as inducing apoptosis, increased the proportion of cells in the G1 phase, particularly in the adenoma cell lines.	seocalcitol	34-40	tumor protein p53	Homo sapiens	49-52
10786699-16	2000	The results implicate Bak protein in the induction of apoptosis by 1alpha,25-dihydroxyvitamin D3 or its analogue EB1089.	seocalcitol	113-119	BCL2 antagonist/killer 1	Homo sapiens	22-25
8651937-8	1996	EB 1089 was clearly more effective than calcitriol in stimulating alkaline phosphatase activity and osteocalcin synthesis.	seocalcitol	0-7	bone gamma-carboxyglutamate protein	Homo sapiens	100-111
10640426-10	2000	These results suggest that EB1089 can inhibit the proliferation of human myeloma cells, especially NCI-H929 cells, via a G(1) block in association with the induction of p27 and the reduction of CDK2 activity.	seocalcitol	27-33	dynactin subunit 6	Homo sapiens	169-172
10640426-10	2000	These results suggest that EB1089 can inhibit the proliferation of human myeloma cells, especially NCI-H929 cells, via a G(1) block in association with the induction of p27 and the reduction of CDK2 activity.	seocalcitol	27-33	cyclin dependent kinase 2	Homo sapiens	194-198
10416587-1	1999	EB1089, an analogue of 1,25 dihydroxyvitamin D with low calcemic activity is a potent inhibitor of parathyroid hormone-related peptide (PTHRP) production in vitro.	seocalcitol	0-6	parathyroid hormone like hormone	Homo sapiens	99-134
10416587-1	1999	EB1089, an analogue of 1,25 dihydroxyvitamin D with low calcemic activity is a potent inhibitor of parathyroid hormone-related peptide (PTHRP) production in vitro.	seocalcitol	0-6	parathyroid hormone like hormone	Homo sapiens	136-141
9846632-8	1998	With the terminal transferase (TdT) assay, 3" DNA breaks indicative of DNA fragmentation were detected histochemically in mammary tumour cells from animals treated with EB1089 (2.5 microg kg(-1)) for 14 days.	seocalcitol	169-175	DNA nucleotidylexotransferase	Homo sapiens	9-29
9846632-8	1998	With the terminal transferase (TdT) assay, 3" DNA breaks indicative of DNA fragmentation were detected histochemically in mammary tumour cells from animals treated with EB1089 (2.5 microg kg(-1)) for 14 days.	seocalcitol	169-175	DNA nucleotidylexotransferase	Homo sapiens	31-34
9492037-0	1998	The noncalcemic vitamin D analogs EB1089 and 22-oxacalcitriol suppress serum-induced parathyroid hormone-related peptide gene expression in a lung cancer cell line.	seocalcitol	34-40	parathyroid hormone like hormone	Homo sapiens	85-120
9081364-0	1996	Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089.	seocalcitol	159-165	insulin	Homo sapiens	14-21
9081364-0	1996	Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089.	seocalcitol	159-165	insulin	Homo sapiens	27-34
8619376-7	1995	EB 1089 was also less effective than 1,25(OH)2D3 in the induction of intestinal but not renal calbindin-D9k mRNA.	seocalcitol	0-7	S100 calcium binding protein G	Mus musculus	94-107
10674019-5	1999	Vitamin D analogues EB1089 and CB1093 inhibited autonomous and IGF-I-stimulated growth of MCF-7 and T47D cells and autonomous growth of IGF-I-insensitive Hs578T cells.	seocalcitol	20-26	insulin like growth factor 1	Homo sapiens	63-68
10674019-5	1999	Vitamin D analogues EB1089 and CB1093 inhibited autonomous and IGF-I-stimulated growth of MCF-7 and T47D cells and autonomous growth of IGF-I-insensitive Hs578T cells.	seocalcitol	20-26	insulin like growth factor 1	Homo sapiens	136-141
9831071-5	1998	In this series, EB1089 proved to be the most potent VD analogue; that is, every structural modification (20-epi configuration, cis-configuration at position C24, or changes at the ethyl groups at position C25) appeared to reduce the determined activities mediated through the VDR of these analogues.	seocalcitol	16-22	vitamin D receptor	Homo sapiens	276-279
9625815-3	1998	We demonstrate that the 1,25(OH)2D3 and its analog EB1089-induced growth inhibition was associated with increased IGFBP-3 mRNA abundance, IGFBP-3 mRNA stability, IGFBP-3 protein accumulation, and decreased IGF-II gene expression.	seocalcitol	51-57	insulin like growth factor binding protein 3	Homo sapiens	114-121
9625815-3	1998	We demonstrate that the 1,25(OH)2D3 and its analog EB1089-induced growth inhibition was associated with increased IGFBP-3 mRNA abundance, IGFBP-3 mRNA stability, IGFBP-3 protein accumulation, and decreased IGF-II gene expression.	seocalcitol	51-57	insulin like growth factor binding protein 3	Homo sapiens	138-145
9625815-3	1998	We demonstrate that the 1,25(OH)2D3 and its analog EB1089-induced growth inhibition was associated with increased IGFBP-3 mRNA abundance, IGFBP-3 mRNA stability, IGFBP-3 protein accumulation, and decreased IGF-II gene expression.	seocalcitol	51-57	insulin like growth factor binding protein 3	Homo sapiens	138-145
9625815-3	1998	We demonstrate that the 1,25(OH)2D3 and its analog EB1089-induced growth inhibition was associated with increased IGFBP-3 mRNA abundance, IGFBP-3 mRNA stability, IGFBP-3 protein accumulation, and decreased IGF-II gene expression.	seocalcitol	51-57	insulin like growth factor 2	Homo sapiens	206-212
9099905-0	1997	The noncalcemic vitamin D analogues EB1089 and 22-oxacalcitriol interact with the vitamin D receptor and suppress parathyroid hormone-related peptide gene expression.	seocalcitol	36-42	vitamin D receptor	Homo sapiens	82-100
9099905-0	1997	The noncalcemic vitamin D analogues EB1089 and 22-oxacalcitriol interact with the vitamin D receptor and suppress parathyroid hormone-related peptide gene expression.	seocalcitol	36-42	parathyroid hormone like hormone	Homo sapiens	114-149
7981122-4	1994	Here, we demonstrate that the VD analogues MC903, EB1089 and KH1060, previously shown to be potent regulators of proliferation and differentiation, are able to act as ligands for VDR and replace VD as a ligand in both nuclear signalling pathways.	seocalcitol	50-56	vitamin D receptor	Homo sapiens	179-182
7756673-5	1995	In both immortalized and neoplastic keratinocytes, EB1089 was 10-100 times more potent than 1,25(OH)2D3 or MC903 on inhibiting PTHRP production.	seocalcitol	51-57	parathyroid hormone like hormone	Homo sapiens	127-132
8514854-0	1993	A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo.	seocalcitol	22-28	parathyroid hormone-like hormone	Rattus norvegicus	39-74
35571391-0	2022	EB1089 promotes the expression of vitamin D receptor in the intestinal epithelial cell line HT-29 and reduces lipopolysaccharide-induced inflammatory response.	seocalcitol	0-6	vitamin D receptor	Homo sapiens	34-52
34069442-5	2021	Activation of VDR with vitamin D (VitD), either calcitriol or its synthetic analog EB1089, sensitized MCF-7-derived, antiestrogen-resistant LCC9 human breast cancer cells to TAM, and attenuated increased UPR and pro-survival autophagy.	seocalcitol	83-89	vitamin D receptor	Homo sapiens	14-17
34069442-7	2021	Further, silencing of VDR impaired sensitivity to TAM in antiestrogen-responsive LCC1 cells, and prevented the effects of calcitriol and EB1089 on UPR and autophagy.	seocalcitol	137-143	vitamin D receptor	Homo sapiens	22-25
35571391-1	2022	Background: EB1089 is a vitamin D receptor (VDR) agonist that reduces the inflammatory response.	seocalcitol	12-18	vitamin D receptor	Homo sapiens	24-42
35571391-1	2022	Background: EB1089 is a vitamin D receptor (VDR) agonist that reduces the inflammatory response.	seocalcitol	12-18	vitamin D receptor	Homo sapiens	44-47
35571391-9	2022	The protein expression levels of Caspase-1, NLRP3, TLR4, MyD88, and NF-kappaB in the LPS + EB1089 group were evidently lower than those in the LPS group; however, the VDR protein expression evidently increased in the LPS + EB1089 group.	seocalcitol	91-97	caspase 1	Homo sapiens	33-42
35571391-9	2022	The protein expression levels of Caspase-1, NLRP3, TLR4, MyD88, and NF-kappaB in the LPS + EB1089 group were evidently lower than those in the LPS group; however, the VDR protein expression evidently increased in the LPS + EB1089 group.	seocalcitol	91-97	NLR family pyrin domain containing 3	Homo sapiens	44-49
35571391-9	2022	The protein expression levels of Caspase-1, NLRP3, TLR4, MyD88, and NF-kappaB in the LPS + EB1089 group were evidently lower than those in the LPS group; however, the VDR protein expression evidently increased in the LPS + EB1089 group.	seocalcitol	91-97	toll like receptor 4	Homo sapiens	51-55
35571391-9	2022	The protein expression levels of Caspase-1, NLRP3, TLR4, MyD88, and NF-kappaB in the LPS + EB1089 group were evidently lower than those in the LPS group; however, the VDR protein expression evidently increased in the LPS + EB1089 group.	seocalcitol	91-97	MYD88 innate immune signal transduction adaptor	Homo sapiens	57-62
35571391-9	2022	The protein expression levels of Caspase-1, NLRP3, TLR4, MyD88, and NF-kappaB in the LPS + EB1089 group were evidently lower than those in the LPS group; however, the VDR protein expression evidently increased in the LPS + EB1089 group.	seocalcitol	91-97	nuclear factor kappa B subunit 1	Homo sapiens	68-77
35571391-9	2022	The protein expression levels of Caspase-1, NLRP3, TLR4, MyD88, and NF-kappaB in the LPS + EB1089 group were evidently lower than those in the LPS group; however, the VDR protein expression evidently increased in the LPS + EB1089 group.	seocalcitol	223-229	vitamin D receptor	Homo sapiens	167-170
35571391-10	2022	Conclusions: EB1089 promoted the VDR expression and reduced the LPS induced inflammation in HT-29 cells.	seocalcitol	13-19	vitamin D receptor	Homo sapiens	33-36
33246442-14	2020	RESULTS: Treatment with proteasome inhibitors and EB1089 resulted in a trend towards an increase in dysferlin and myogenin expression.	seocalcitol	50-56	dysferlin	Homo sapiens	100-109
33246442-14	2020	RESULTS: Treatment with proteasome inhibitors and EB1089 resulted in a trend towards an increase in dysferlin and myogenin expression.	seocalcitol	50-56	myogenin	Homo sapiens	114-122
33246442-15	2020	Furthermore, EB1089 and proteasome inhibitors reduced the release of TSP-1 in myotubes.	seocalcitol	13-19	thrombospondin 1	Homo sapiens	69-74
30455079-14	2018	We treated NK-LGLL patient PBMCs with calcitriol or EB1089 and found decreased p-STAT1 and p-STAT3 while VDR increased, which matched the NKL cell line data.	seocalcitol	52-58	signal transducer and activator of transcription 1	Homo sapiens	81-86
30961641-6	2019	Western blot analyses showed that treatment of L428 cells with the VDAs (calcipotriol and EB1089) resulted in modest increases in nuclear accumulation of VDR (nuVDR) compared to either dimethyl sulfoxide (DMSO) or VD3 treatments.	seocalcitol	90-96	vitamin D receptor	Homo sapiens	154-157
30455079-11	2018	Both calcitriol and EB1089 caused significant upregulation of the vitamin D receptor (VDR).	seocalcitol	20-26	vitamin D receptor	Homo sapiens	66-84
30455079-11	2018	Both calcitriol and EB1089 caused significant upregulation of the vitamin D receptor (VDR).	seocalcitol	20-26	vitamin D receptor	Homo sapiens	86-89
30455079-12	2018	IL-2 induction of p-STAT1 and p-STAT3 phosphorylation was significantly decreased after calcitriol or EB1089 treatment.	seocalcitol	102-108	interleukin 2	Homo sapiens	0-4
30455079-12	2018	IL-2 induction of p-STAT1 and p-STAT3 phosphorylation was significantly decreased after calcitriol or EB1089 treatment.	seocalcitol	102-108	signal transducer and activator of transcription 1	Homo sapiens	20-25
30455079-12	2018	IL-2 induction of p-STAT1 and p-STAT3 phosphorylation was significantly decreased after calcitriol or EB1089 treatment.	seocalcitol	102-108	signal transducer and activator of transcription 3	Homo sapiens	32-37
30455079-13	2018	Additionally, IL-10, interferon (IFN)-gamma, and FMS-like tyrosine kinase 3 ligand (Flt-3L) extracellular output was significantly decreased at 100 nM EB1089 and intracellular IL-10 was decreased with either calcitriol or EB1089 treatment.	seocalcitol	151-157	interleukin 10	Homo sapiens	14-19
30455079-13	2018	Additionally, IL-10, interferon (IFN)-gamma, and FMS-like tyrosine kinase 3 ligand (Flt-3L) extracellular output was significantly decreased at 100 nM EB1089 and intracellular IL-10 was decreased with either calcitriol or EB1089 treatment.	seocalcitol	151-157	interferon gamma	Homo sapiens	21-43
30455079-13	2018	Additionally, IL-10, interferon (IFN)-gamma, and FMS-like tyrosine kinase 3 ligand (Flt-3L) extracellular output was significantly decreased at 100 nM EB1089 and intracellular IL-10 was decreased with either calcitriol or EB1089 treatment.	seocalcitol	151-157	fms related receptor tyrosine kinase 3 ligand	Homo sapiens	49-82
30455079-13	2018	Additionally, IL-10, interferon (IFN)-gamma, and FMS-like tyrosine kinase 3 ligand (Flt-3L) extracellular output was significantly decreased at 100 nM EB1089 and intracellular IL-10 was decreased with either calcitriol or EB1089 treatment.	seocalcitol	151-157	fms related receptor tyrosine kinase 3 ligand	Homo sapiens	84-90
30455079-13	2018	Additionally, IL-10, interferon (IFN)-gamma, and FMS-like tyrosine kinase 3 ligand (Flt-3L) extracellular output was significantly decreased at 100 nM EB1089 and intracellular IL-10 was decreased with either calcitriol or EB1089 treatment.	seocalcitol	222-228	interleukin 10	Homo sapiens	14-19
30455079-13	2018	Additionally, IL-10, interferon (IFN)-gamma, and FMS-like tyrosine kinase 3 ligand (Flt-3L) extracellular output was significantly decreased at 100 nM EB1089 and intracellular IL-10 was decreased with either calcitriol or EB1089 treatment.	seocalcitol	222-228	fms related receptor tyrosine kinase 3 ligand	Homo sapiens	84-90
30455079-13	2018	Additionally, IL-10, interferon (IFN)-gamma, and FMS-like tyrosine kinase 3 ligand (Flt-3L) extracellular output was significantly decreased at 100 nM EB1089 and intracellular IL-10 was decreased with either calcitriol or EB1089 treatment.	seocalcitol	222-228	interleukin 10	Homo sapiens	176-181
30455079-14	2018	We treated NK-LGLL patient PBMCs with calcitriol or EB1089 and found decreased p-STAT1 and p-STAT3 while VDR increased, which matched the NKL cell line data.	seocalcitol	52-58	signal transducer and activator of transcription 3	Homo sapiens	93-98
28744399-5	2017	Addition of calcitriol or EB1089 to TKIs treatment induced more effective inhibiting effect on cell growth and AKT and MAPK phosphorylation than all compounds alone.	seocalcitol	26-32	AKT serine/threonine kinase 1	Homo sapiens	111-114
25460500-5	2014	Here we report that two non-calcemic analogues of 1alpha,25-dihydroxyvitamin D3, seocalcitol (EB1089) and QW-1624F2-2, collaborate with BRCA1 in mediating growth inhibition of breast cancer cells and breast cancer stem-like cells.	seocalcitol	81-92	BRCA1 DNA repair associated	Homo sapiens	136-141
27458123-11	2016	Although TM with and without 1,25-(OH)2D3 had no effect on VDR expression, inhibition of VDR expression via siRNA prevented 1,25-(OH)2D3, ZK191784, EB1089, and 24,25-dihydroxyvitamin D3 from inhibiting dextrose-mediated SO generation.	seocalcitol	148-154	vitamin D receptor	Homo sapiens	89-92
26704532-10	2016	Furthermore, CYP24A1 mRNA levels in NSC-34 cells were up-regulated by 1alpha,25(OH)2D3 and its synthetic analogs, EB1089 and tacalcitol.	seocalcitol	114-120	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	13-20
25542307-11	2015	In addition, both glucose and HIV stimulated kidney cell ROS generation and DNA damage and compromised DNA repair; however, tempol (superoxide dismutase mimetic), losartan (Ang II blocker) and EB1089 (VDR agonist) provided protection against DNA damaging effects of glucose and HIV.	seocalcitol	193-199	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	201-204
26750780-3	2015	Catalase mRNA was increased in response to calcitriol (10(-7) M), and seocalcitol (10(-7) and 10(-9) M).	seocalcitol	70-81	catalase	Canis lupus familiaris	0-8
26750780-5	2015	Catalase enzymatic activity increased in response to calcitriol, seocalcitol and analogue V (10(-9) M).	seocalcitol	65-76	catalase	Canis lupus familiaris	0-8
25501129-7	2015	Treatment of PDAC cells with 1,25-dihydroxyvitamin D3 (1,25D), its synthetic analogue EB1089 (EB), and VDR transgenics drastically inhibited FOXM1 signaling and markedly suppressed tumor stemness, growth, and metastasis.	seocalcitol	86-92	forkhead box M1	Homo sapiens	141-146
25501129-7	2015	Treatment of PDAC cells with 1,25-dihydroxyvitamin D3 (1,25D), its synthetic analogue EB1089 (EB), and VDR transgenics drastically inhibited FOXM1 signaling and markedly suppressed tumor stemness, growth, and metastasis.	seocalcitol	86-88	forkhead box M1	Homo sapiens	141-146
25460500-5	2014	Here we report that two non-calcemic analogues of 1alpha,25-dihydroxyvitamin D3, seocalcitol (EB1089) and QW-1624F2-2, collaborate with BRCA1 in mediating growth inhibition of breast cancer cells and breast cancer stem-like cells.	seocalcitol	94-100	BRCA1 DNA repair associated	Homo sapiens	136-141
25252917-7	2014	EB1089 did not alter HFD-induced increase in serum leptin levels but increased miR-498 and decreased the diet-induced hTERT expression in tumors.	seocalcitol	0-6	microRNA 498	Homo sapiens	79-86
25252917-7	2014	EB1089 did not alter HFD-induced increase in serum leptin levels but increased miR-498 and decreased the diet-induced hTERT expression in tumors.	seocalcitol	0-6	telomerase reverse transcriptase	Homo sapiens	118-123
24242708-0	2014	Vitamin D receptor agonist EB1089 is a potent regulator of prostatic "intracrine" metabolism.	seocalcitol	27-33	vitamin D receptor	Homo sapiens	0-18
20714323-3	2011	In this study, we show that 1,25 vitamin D3 and its analogues EB1089 and KH1060 potently inhibit CEACAM1 expression in cancer cells.	seocalcitol	62-68	CEA cell adhesion molecule 1	Homo sapiens	97-104
22763121-4	2012	On the other hand, a VDR agonist (EB1089) enhanced T cell VDR expression both under basal and morphine-stimulated states.	seocalcitol	34-40	vitamin D receptor	Homo sapiens	21-24
22763121-4	2012	On the other hand, a VDR agonist (EB1089) enhanced T cell VDR expression both under basal and morphine-stimulated states.	seocalcitol	34-40	vitamin D receptor	Homo sapiens	58-61
22647636-4	2012	On the other hand, EB-1089, a VDR agonist (VD), inhibited both downregulation of VDR and tubular cell DNA injury in the HIV milieu.	seocalcitol	19-26	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	30-33
22647636-4	2012	On the other hand, EB-1089, a VDR agonist (VD), inhibited both downregulation of VDR and tubular cell DNA injury in the HIV milieu.	seocalcitol	19-26	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	81-84
23467424-5	2013	Moreover, CIDHPs lacking VDR displayed enhanced ANG II production, and treatment of HIV/CIDHPs with EB1089 (vitamin D3; VD) attenuated ANG II production.	seocalcitol	100-106	angiogenin	Homo sapiens	135-138
21843606-5	2011	Positive regulation of 25OHase mRNA level after the treatment with vitamin D3 was observed in liver, while in kidney, vitamin D3 and Seocalcitol induced expression of 24OHase was significant.	seocalcitol	133-144	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	167-174